STORM Therapeutics (STORM), a Cambridge-based BioTech company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced that it has secured €47.5 million ($56 million) in Series C financing.
The financing was secured from existing investors, M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, the UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), and Fast Track Initiative (FTI).
Jerry McMahon, Chief Executive Officer of STORM Therapeutics, said, “Advancing our first‑in‑class METTL3 inhibitor, STC-15, into Phase 2 clinical development marks a pivotal breakthrough in tackling cancers characterised by aberrant cell differentiation. This milestone highlights our scientific innovation and the potential to create new therapeutic options for patients with substantial unmet needs.
“We are grateful for the steadfast support from our investors and are encouraged by the robust durability and activity demonstrated with STC-15 in Phase 1 studies. As we begin our Phase 2 trial, our focus remains on addressing critical unmet needs in sarcoma for the benefit of patients.”
Founded in 2015, STORM Therapeutics is a clinical-stage BioTech company targeting RNA modifications to reprogram malignant cells and treat disease. STORM’s lead candidate, STC-15, is the first RNA-modifying enzyme inhibitor to enter human clinical trials, claims the company.
STC-15 specifically inhibits METTL3, an RNA-modifying enzyme involved in the regulation of cancer stem cell differentiation, a critical process in the development of sarcomas and other malignancies.
According to the company, the proceeds from this funding will support the advancement of STC-15, including funding the company’s Phase 2 monotherapy study in selected sarcoma indications, in which the first patient has now been successfully dosed. Sarcoma is a form of cancer that arises in bone or soft tissues, including muscle, fat, cartilage, blood vessels, and other connective or supportive tissue.
This study is designed to support a potential accelerated regulatory approval pathway for STC-15 and to establish a foundation for subsequent clinical development across additional oncology indications, says the company.
In a Phase 1 monotherapy trial, STC-15 showed durable tumour regression across various sarcoma subtypes, highlighting its potential to target and reprogram progenitor cells that develop into cancer cells. These results will be presented at an upcoming medical conference in 2026.
STORM states that its sarcoma programme builds on previous clinical and translational research in epitranscriptomic regulation, emphasising the importance of RNA-modifying enzymes in the maintenance of stem cell‑derived tumours and their potential application in broader settings.
“METTL3 methylates mRNA, influencing the differentiation processes of connective tissues and other cell types. Sarcomas arise from transformed mesenchymal stem cells as they progress into malignant connective tissue cells, accounting for 1% of adult cancers and 15% of pediatric cancers. Due to the frequent absence of driver mutations or immunogenic features amenable to standard treatments, sarcomas depend on METTL3-driven methylation for growth and survival,” explained the company.
The Phase 2 trial will assess the anti-tumour effects of inhibiting mRNA methylation in sarcomas.
Read the orginal article: https://www.eu-startups.com/2026/04/storm-therapeutics-raises-e47-5-million-series-c-to-harness-the-power-of-rna-modification-to-treat-cancer/
